Drug-Induced Phospholipidosis Services
Drug induced phospholipidosis (DIPL) is a phospholipid storage disorder characterized by an excessive accumulation of multi-lamellar bodies (myeloid bodies) in cells and tissues. Currently more than 350 drug candidates and marketed drugs have been reported to cause DIPL. DIPL has been considered an adverse finding from a regulatory perspective whether justified or not. Since DIPL may be linked to unwanted toxicities, it is important for pharmaceutical researchers and physicians to better understand, track, and manage this drug side effect.
Bis(mono)acylglycerol phosphate (BMP) is a lysosomal phospholipid that is increased in the tissues of animals and humans with DIPL and NPC disease. A specific species of BMP, di-docosahexaenoyl (22:6)-BMP (di-22:6-BMP), is a biomarker of DIPL in humans and animals that can be monitored in the plasma/serum, urine and tissues[3-6].
In vitro Drug-Induced Phospholipidosis Screening
The in vitro analysis of di-22:6-BMP provides a sensitive and specific high throughput screening assay to rapidly identify compounds with the potential to induce DIPL early in the drug discovery process.
Nonclinical & Clinical Studies
Nextcea uses validated high sensitivity LC-MS/MS methods to measure the concentrations of di-22:6-BMP in biological samples from nonclinical and clinical studies.
◄ Case Study: Amiodarone and Chloroquine
Levels of di-22:6-BMP in the urine of rats treated with 150 mg/kg/day of amiodarone and 120 mg/kg/day of chloroquine (Liu et al. Toxicology and Applied Pharmacology 2014; 279:467-476) Download the abstract